Compare Lowe`s Companies Inc (LOW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lowe`s Companies Inc trades at $185.93 (market cap $105.96B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LOW | VRTX | |
|---|---|---|
Market Cap | $105.96B | $127.55B |
Volume | 4,039,547 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $557.96 |
52-Week Low | $179.50 | $407.37 |
Typical Hold Time | 98 Days | 120 Days |
Enterprise Value | $144.81B | $121.68B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $185.27, up 2.05% today, but faces a bearish technical signal with key resistance at $191. The company reported Q2 2026 EPS of $4.40, beating estimates, yet revenue has declined from $96.2B in 2022 to $83.7B in 2025. Analysts maintain a strong buy consensus with a $244.09 price target, citing value despite industry headwinds. Recent news highlights drone delivery innovation with DoorDash and Alphabet's Wing, aiming to enhance customer convenience.
LOW presents a value opportunity with a P/E of 15.96 and bullish analyst sentiment, but risks include a challenging housing market and declining revenue trends. The stock's upside hinges on execution of new initiatives and economic recovery in home improvement spending, with near-term volatility expected amid macroeconomic uncertainty.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
